Effect of omega-3 supplementation vs. placebo on blood lipid levels in patients with ischemic heart disease: a systematic review and meta-analysis.
Nutr Metab Cardiovasc DisApr 16, 2026 (epub)
Clinical ResearchCardiology
Ammar Yasser Negm, Abdullah Samir Ashour, Mustafa Youssef Mohamed et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the effects of omega-3 supplementation on lipid profiles in patients with ischemic heart disease (IHD). Analyzing data from ten randomized controlled trials involving 633 participants, the study found that omega-3 significantly reduced triglycerides by 17.53 mg/dL and LDL-C by 9.43 mg/dL, suggesting its potential role in managing dyslipidemia in IHD patients.
Key findings
- Omega-3 supplementation reduced triglycerides by 17.53 mg/dL (95% CI: -30.64 to -4.41; p = 0.009).
- LDL-C levels decreased by 9.43 mg/dL (95% CI: -14.20 to -4.65; p = 0.0001).
- A trend towards total cholesterol reduction was observed (MD: -6.03 mg/dL, p = 0.05).
- HDL-C increased by 1.66 mg/dL post-sensitivity analysis (p = 0.03).
Why it matters
The findings highlight the potential of omega-3 fatty acids as an adjunctive therapy for managing lipid levels in patients with ischemic heart disease, particularly in those who do not achieve optimal lipid control with statins alone.